MYMD

MyMD Pharmaceuticals (MYMD)

MyMD Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:MYMD

1 2 3 4 5 6 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/31	21:00	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/05/31	21:00	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/05/24	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/05/21	22:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/05/21	22:00	Business Wire	MyMD Pharmaceuticals Secures Strategic Investments	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/05/17	06:30	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/05/16	06:01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/03/08	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/03/06	01:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/03/05	23:15	Business Wire	MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/02/15	05:13	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/02/15	01:27	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/02/14	06:57	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2024/02/14	01:45	Business Wire	MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/12/06	23:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/12/06	23:15	Business Wire	MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/10/19	22:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/10/19	22:00	Business Wire	MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/10/14	06:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/10/05	05:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/10/04	20:30	Business Wire	MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/09/09	06:24	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/08/25	06:58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/08/19	05:21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/08/15	06:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/08/14	21:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/08/14	21:30	Business Wire	FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/08/04	05:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/08/02	21:30	Business Wire	MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results	NASDAQ:MYMD	MyMD Pharmaceuticals Inc
2023/08/02	05:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYMD	MyMD Pharmaceuticals Inc